On June 30, Micot Pharma-B declined 5.03% in regular trading, trading at 36.36 HKD/share, with turnover of approximately 29.26 million HKD.

The stock listed on the Hong Kong Stock Exchange on June 24 at an IPO price of 18.20 HKD and surged 102.75% on its debut day. The Hong Kong public offering was oversubscribed approximately 1,181.46 times, and the share price reached as high as 40 HKD post-listing, more than doubling from the offer price. The rapid rally accumulated significant floating profits, and profit-taking pressure has persisted, with similar pullback patterns observed on June 26 and June 29.

As an 18A-listed pre-revenue biotech company, Micot Pharma's core product MT1013 remains in Phase III clinical trials, with commercialization not expected until early 2028, offering no near-term revenue contribution. The continued unwinding of early gains has driven the ongoing correction.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)